Phosphodiesterase type III and IV enzymes (PDE3/PDE4)

Phosphodiesterase type III and IV enzymes are members of the cyclic nucleotide phosphodiesterase superfamily, responsible for catalyzing the hydrolysis of cAMP and, in the case of PDE3, also cGMP. PDE3 is predominantly expressed in heart muscle, vascular smooth muscle, and platelets; its inhibition leads to increased cAMP, causing increased contractility, vasodilation, and anti-platelet effects. PDE4 is mainly expressed in immune and inflammatory cells and the lungs; its inhibition increases cAMP, mediating anti-inflammatory and bronchodilatory effects. Both enzyme families have multiple isoforms with tissue-specific expression and play key roles in diseases such as heart failure, COPD, inflammation, and some cancers[1][2][3][4][5][6]. Selective inhibitors of PDE3 and PDE4 are used clinically and in research, but their application is limited by safety concerns specific to their tissue actions and pharmacological effects.

Other names

PDE3 (for type III)PDE4 (for type IV)cAMP phosphodiesterase (family-specific alias)cAMP-specific phosphodiesterase (PDE4 family)

Inhibition of PDE3 increases cAMP in myocardium and vascular smooth muscle, leading to inotropic and vasodilatory effects and inhibition of platelet aggregation. Inhibition of PDE4 increases cAMP in immune and bronchial cells, leading to reduced inflammation, bronchial relaxation, and decreased production of pro-inflammatory mediators. Nonselective inhibition (e.g., by ibudilast) can act across multiple PDEs to reduce inflammation and provide bronchodilation.